,text,position,name,last,events,dateString,collapsed,checked
0,"<p>New funding applications are referred to one of Pharmac's Funding Application Advisors (FAAs), who'll review the application to ensure they have the relevant information to undertake a preliminary analysis.&nbsp; They may seek more information if required.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/new-funding-applications/</a></p>",0,Application Received,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Oct 2019', 'fs': 'Oct 2019', 'change': None}, 'Event_Description': {'s': 'Application received', 'fs': 'Application received', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ0000033IgL2AU'}, 'Id': 'a0POZ0000033IgL2AU', 'Event_Date__c': '2019-10-21', 'Event_Description__c': 'Application received', 'Stage__c': 'Application Received', 'Formatted_Date__c': 'Oct 2019', 'Status_History__c': 'a132P000000BnEpQAK'}, 'change': None}, {'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jul 2020', 'fs': 'Jul 2020', 'change': None}, 'Event_Description': {'s': 'Awaiting registration with Medsafe.', 'fs': 'Awaiting registration with Medsafe.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ0000033IgM2AU'}, 'Id': 'a0POZ0000033IgM2AU', 'Event_Date__c': '2020-07-07', 'Event_Description__c': 'Awaiting registration with Medsafe.', 'Stage__c': 'Application Received', 'Formatted_Date__c': 'Jul 2020', 'Status_History__c': 'a132P000000BvrCQAS'}, 'change': None}]",Oct 2019,False,True
1,"<p>Pharmac is identifying and gathering information required to get clinical advice.  The <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/"" rel=""nofollow"">Pharmacology and Therapeutics Advisory Committee (PTAC)</a>  meets quarterly. There are also around 20 expert <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/"" rel=""nofollow"">Specialist Advisory Committees (SACs)</a>, previously expert Subcommittees, which provide clinical evaluations in specialist areas. Specialist Advisory Committees meet as required to discuss issues referred to them by PTAC or Pharmac.</p>
<p style=""height: 20px"">&nbsp;</p>
<p>In November 2021, we introduced separate terms of reference for the SACs to make clear that these committees have different, but complementary, roles, expertise and perspectives to PTAC.</p>
<p style=""height: 15px"">&nbsp;</p>
<p>PTAC and SACs may make recommendations to Pharmac that differ from each other when looking at the same evidence. Pharmac considers the recommendations provided by all our clinical advisory committees when assessing applications.</p>
<p style=""height: 20px"">&nbsp;</p>
<p><a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/pharmacology-and-therapeutics-advisory-committee-ptac/ptac-terms-of-reference-july-2021/"" rel=""nofollow"">PTAC</a>  and <a class=""external-link"" href=""https://pharmac.govt.nz/about/expert-advice/specialist-advisory-committees/specialist-advisory-committee-terms-of-reference//"" rel=""nofollow"">Specialist Advisory Committees</a> records of the meeting will be published on this website in accordance with the Terms of Reference.</p>",1,Seeking Clinical Advice,False,"[{'Summary': {'s': '<p>Lumacaftor/ivacaftor (ORKAMBI) was discussed by the Respiratory Subcommittee of PTAC at its meeting on Thursday 26 August 2021 during the discussion on Elexacaftor/tezacaftor/ivacaftor and ivacaftor (ELX/TEZ/IVA) (Trikafta®). The Subcommittee noted that: 1.24. Study 107 (ClinicalTrials.gov Identifier: NCT04183790): a roll-over study from Study 106 investigating the long-term safety, tolerability, efficacy, and pharmacodynamics of ELX/TEZ/IVA in patients with CF aged between 6 and 11 years. The Subcommittee noted an indirect comparison of ELX/TEZ/IVA against placebo, lumacaftor (LUM)/IVA and TEZ/IVA and IVA alone submitted by the supplier. The Subcommittee considered that it was an appropriately designed network meta-analysis that included consistent trial designs and study populations (limited to those aged 12 and over) for comparison, large effect sizes, consistent results across outcome measures, and evidence of a dose response that indicated that triple therapy (ELX/TEZ/IVA) was more effective than double or single therapies, which were in turn more effective than best supportive care.</p><p><br></p><p>Please see the following record for further information:</p><p>https://pharmac.govt.nz/assets/2021-08-26-Respiratory-Subcommittee-record-.pdf</p>', 'fs': '<p>Lumacaftor/ivacaftor (ORKAMBI) was discussed by the Respiratory Subcommittee of PTAC at its meeting on Thursday 26 August 2021 during the discussion on Elexacaftor/tezacaftor/ivacaftor and ivacaftor (ELX/TEZ/IVA) (Trikafta®). The Subcommittee noted that: 1.24. Study 107 (ClinicalTrials.gov Identifier: NCT04183790): a roll-over study from Study 106 investigating the long-term safety, tolerability, efficacy, and pharmacodynamics of ELX/TEZ/IVA in patients with CF aged between 6 and 11 years. The Subcommittee noted an indirect comparison of ELX/TEZ/IVA against placebo, lumacaftor (LUM)/IVA and TEZ/IVA and IVA alone submitted by the supplier. The Subcommittee considered that it was an appropriately designed network meta-analysis that included consistent trial designs and study populations (limited to those aged 12 and over) for comparison, large effect sizes, consistent results across outcome measures, and evidence of a dose response that indicated that triple therapy (ELX/TEZ/IVA) was more effective than double or single therapies, which were in turn more effective than best supportive care.</p><p><br></p><p>Please see the following record for further information:</p><p>https://pharmac.govt.nz/assets/2021-08-26-Respiratory-Subcommittee-record-.pdf</p>', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Oct 2021', 'fs': 'Oct 2021', 'change': None}, 'Event_Description': {'s': 'Clinical advice received from  at meeting TBD.', 'fs': 'Clinical advice received from  at meeting TBD.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ0000033IgN2AU'}, 'Id': 'a0POZ0000033IgN2AU', 'Event_Date__c': '2021-10-01', 'Event_Description__c': 'Clinical advice received from  at meeting TBD.', 'Stage__c': 'Seeking Clinical Advice', 'Summary__c': '<p>Lumacaftor/ivacaftor (ORKAMBI) was discussed by the Respiratory Subcommittee of PTAC at its meeting on Thursday 26 August 2021 during the discussion on Elexacaftor/tezacaftor/ivacaftor and ivacaftor (ELX/TEZ/IVA) (Trikafta®). The Subcommittee noted that: 1.24. Study 107 (ClinicalTrials.gov Identifier: NCT04183790): a roll-over study from Study 106 investigating the long-term safety, tolerability, efficacy, and pharmacodynamics of ELX/TEZ/IVA in patients with CF aged between 6 and 11 years. The Subcommittee noted an indirect comparison of ELX/TEZ/IVA against placebo, lumacaftor (LUM)/IVA and TEZ/IVA and IVA alone submitted by the supplier. The Subcommittee considered that it was an appropriately designed network meta-analysis that included consistent trial designs and study populations (limited to those aged 12 and over) for comparison, large effect sizes, consistent results across outcome measures, and evidence of a dose response that indicated that triple therapy (ELX/TEZ/IVA) was more effective than double or single therapies, which were in turn more effective than best supportive care.</p><p><br></p><p>Please see the following record for further information:</p><p>https://pharmac.govt.nz/assets/2021-08-26-Respiratory-Subcommittee-record-.pdf</p>', 'Formatted_Date__c': 'Oct 2021', 'Status_History__c': 'a13OZ0000013wgdYAA'}, 'change': None}]",Oct 2021,False,True
2,"<p>Following Clinical Advice, Pharmac staff considers the advice and the funding application under goes an assessment using our&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/factors-for-consideration/"" rel=""nofollow"">Factors for Consideration</a>&nbsp;framework and seeks additional information as required.</p>
<p>&nbsp;</p>
<p>Research and Economic analysis are undertaken.&nbsp; This focuses on the costs and benefits of a proposed course of action. Economics is based on three fundamental concepts that summarise the issues Pharmac faces daily:&nbsp;</p>
<ul>
<li>Scarcity &ndash; resources will always be insufficient to support all possible activities.</li>
<li>Choices &ndash; due to scarce resources, decisions must be made about how best to use them.</li>
<li>Opportunity cost &ndash; by choosing to use resources one way, we forgo other opportunities to use the same resources.</li>
</ul>
<p>&nbsp;</p>
<p>For further information on the purpose of, and techniques for, undertaking economic analysis in health care, please refer&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/economic-analysis/</a></p>",2,Under Assessment,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jul 2023', 'fs': 'Jul 2023', 'change': None}, 'Event_Description': {'s': 'Working to compare options', 'fs': 'Working to compare options', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ0000033IgO2AU'}, 'Id': 'a0POZ0000033IgO2AU', 'Event_Date__c': '2023-07-04', 'Event_Description__c': 'Working to compare options', 'Stage__c': 'Under Assessment', 'Formatted_Date__c': 'Jul 2023', 'Status_History__c': 'a132P000000F3mEQAS'}, 'change': None}]",Jul 2023,False,True
3,"<p>Pharmac staff uses a prioritisation process to compare and rank funding options. Possible opportunities for new investment will always exceed the budget Pharmac has available; therefore, prioritisation is an intrinsic part of Pharmac’s decision-making process.</p>
<p>The relative ranking of options aims to support Pharmac&rsquo;s statutory objective &ldquo;to secure for eligible people in need of pharmaceuticals, the best health outcomes that are reasonably achievable from pharmaceutical treatment and from within the amount of funding provided&rdquo;.</p>
<p>A funding application or proposal is considered ready for prioritisation when sufficient information is available to permit it to be reviewed against Pharmac's Factors for Consideration and to inform a comparison with other possible investment decisions.</p>
<p>There is no guarantee when or if a ranked medicine will be funded.&nbsp;&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/prioritisation/</a></p>",3,Options Compared,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Jul 2023', 'fs': 'Jul 2023', 'change': None}, 'Event_Description': {'s': 'The relative ranking of the pharmaceutical application has been completed.', 'fs': 'The relative ranking of the pharmaceutical application has been completed.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ0000033IgP2AU'}, 'Id': 'a0POZ0000033IgP2AU', 'Event_Date__c': '2023-07-06', 'Event_Description__c': 'The relative ranking of the pharmaceutical application has been completed.', 'Stage__c': 'Options Compared', 'Formatted_Date__c': 'Jul 2023', 'Status_History__c': 'a132P000000FC9GQAW'}, 'change': None}]",Jul 2023,False,True
4,"<p>Pharmac is consulting on a proposal to either approve or decline the application.&nbsp;We seek the views of all people who have an interest in our proposals, or who may be affected by them, to obtain feedback on our proposed approaches.</p>
<p><a class=""external-link"" href=""https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/"" rel=""nofollow"">https://www.pharmac.govt.nz/medicines/how-medicines-are-funded/having-your-say/</a></p>",4,Under Consultation,False,"[{'Summary': {'s': '<p><span style=""color: rgb(68, 68, 68);"">We are proposing to decline this application because since</span> this application was received we have funded an alternative medicine <a href=""https://connect.pharmac.govt.nz/apptracker/s/application-public/a102P00000BJo9L/p001708"" target=""_blank"">elexacaftor with tezacaftor and ivacaftor triple therapy (Trikafta)</a> for cystic fibrosis in people aged 6 years and over with F508del gene mutations</p>', 'fs': '<p><span style=""color: rgb(68, 68, 68);"">We are proposing to decline this application because since</span> this application was received we have funded an alternative medicine <a href=""https://connect.pharmac.govt.nz/apptracker/s/application-public/a102P00000BJo9L/p001708"" target=""_blank"">elexacaftor with tezacaftor and ivacaftor triple therapy (Trikafta)</a> for cystic fibrosis in people aged 6 years and over with F508del gene mutations</p>', 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2023-08-02-proposal-to-decline-inactive-funding-applications"" target=""_blank"" style=""font-size: 14px; background-color: white;"">Consultation notification</a></p>', 'fs': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2023-08-02-proposal-to-decline-inactive-funding-applications"" target=""_blank"" style=""font-size: 14px; background-color: white;"">Consultation notification</a></p>', 'change': None}, 'Formatted_Date': {'s': 'Aug 2023', 'fs': 'Aug 2023', 'change': None}, 'Event_Description': {'s': 'Public consultation for this application is active.', 'fs': 'Public consultation for this application is active.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ0000033IgQ2AU'}, 'Id': 'a0POZ0000033IgQ2AU', 'Event_Date__c': '2023-08-01', 'Event_Description__c': 'Public consultation for this application is active.', 'Stage__c': 'Under Consultation', 'Links__c': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2023-08-02-proposal-to-decline-inactive-funding-applications"" target=""_blank"" style=""font-size: 14px; background-color: white;"">Consultation notification</a></p>', 'Summary__c': '<p><span style=""color: rgb(68, 68, 68);"">We are proposing to decline this application because since</span> this application was received we have funded an alternative medicine <a href=""https://connect.pharmac.govt.nz/apptracker/s/application-public/a102P00000BJo9L/p001708"" target=""_blank"">elexacaftor with tezacaftor and ivacaftor triple therapy (Trikafta)</a> for cystic fibrosis in people aged 6 years and over with F508del gene mutations</p>', 'Formatted_Date__c': 'Aug 2023', 'Status_History__c': 'a13OZ0000019ZviYAE'}, 'change': None}]",Aug 2023,False,True
5,"<p>Following the consultation process, Pharmac staff considers the feedback and identifies any additional information required as part of a gap analysis.&nbsp; The proposal may require further clinical advice, research, and assessment.</p>",5,Reviewing Consultation Feedback,False,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': None, 'fs': None, 'change': None}, 'Formatted_Date': {'s': 'Sep 2023', 'fs': 'Sep 2023', 'change': None}, 'Event_Description': {'s': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'fs': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ0000033IgR2AU'}, 'Id': 'a0POZ0000033IgR2AU', 'Event_Date__c': '2023-09-02', 'Event_Description__c': 'Public consultation for this application is now closed. Pharmac is reviewing consultation feedback.', 'Stage__c': 'Reviewing Consultation Feedback', 'Formatted_Date__c': 'Sep 2023', 'Status_History__c': 'a13OZ000004YgVbYAK'}, 'change': None}]",Sep 2023,False,True
6,"<p>We refer to our decisions about whether and how particular pharmaceuticals are publicly-funded, as &ldquo;funding decisions&rdquo;.</p>
<p>We consider and assess all funding decisions using the&nbsp;<a class=""external-link"" href=""https://www.pharmac.govt.nz/about/operating-policies-and-procedures/#factorsfc"" rel=""nofollow"">Factors for Consideration</a>. When we do so, we carefully evaluate clinical and other evidence for the benefits and suitability of a proposal, and to identify and understand the people who will be affected by it.</p>
<p>While our main task is to allocate pharmaceutical funding, we consider the benefits and costs across the whole health system now and with a long-term focus, including the effects for hospitals and primary care, and consider direct costs to patients as well as to all health sector budgets.</p>
<p>Final funding decisions are made by the Pharmac Board or delegated to senior Pharmac staff as required by the Board.</p>
<p>&nbsp;</p>",6,Decision,True,"[{'Summary': {'s': None, 'fs': None, 'change': None}, 'Published_Recommendation': {'s': None, 'fs': None, 'change': None}, 'Published_Discussion': {'s': None, 'fs': None, 'change': None}, 'Published_Application': {'s': None, 'fs': None, 'change': None}, 'PTAC_Comments': {'s': None, 'fs': None, 'change': None}, 'Outcome': {'s': None, 'fs': None, 'change': None}, 'Links': {'s': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2023-11-07-decision-to-decline-inactive-applications-for-the-funding-of-some-medicines"" target=""_blank"" style=""font-size: 14px;"">Decision notified</a></p>', 'fs': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2023-11-07-decision-to-decline-inactive-applications-for-the-funding-of-some-medicines"" target=""_blank"" style=""font-size: 14px;"">Decision notified</a></p>', 'change': None}, 'Formatted_Date': {'s': 'Nov 2023', 'fs': 'Nov 2023', 'change': None}, 'Event_Description': {'s': 'The funding application has been declined.', 'fs': 'The funding application has been declined.', 'change': None}, 'e': {'attributes': {'type': 'Application_Event__c', 'url': '/services/data/v65.0/sobjects/Application_Event__c/a0POZ0000033IgS2AU'}, 'Id': 'a0POZ0000033IgS2AU', 'Event_Date__c': '2023-11-07', 'Event_Description__c': 'The funding application has been declined.', 'Stage__c': 'Decision', 'Links__c': '<p><a href=""https://pharmac.govt.nz/news-and-resources/consultations-and-decisions/2023-11-07-decision-to-decline-inactive-applications-for-the-funding-of-some-medicines"" target=""_blank"" style=""font-size: 14px;"">Decision notified</a></p>', 'Formatted_Date__c': 'Nov 2023', 'Status_History__c': 'a13OZ000004YhWTYA0'}, 'change': None}]",Nov 2023,False,True
